229 related articles for article (PubMed ID: 34761877)
1. Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-induced senescence in breast cancer cells.
Kartika ID; Kotani H; Iida Y; Koyanagi A; Tanino R; Harada M
Cancer Med; 2021 Dec; 10(24):8988-8999. PubMed ID: 34761877
[TBL] [Abstract][Full Text] [Related]
2. Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity.
Inao T; Kotani H; Iida Y; Kartika ID; Okimoto T; Tanino R; Shiba E; Harada M
Cancer Sci; 2019 Sep; 110(9):2690-2699. PubMed ID: 31250942
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
[TBL] [Abstract][Full Text] [Related]
4. IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Zuo S; Liu C; Wang J; Wang F; Xu W; Cui S; Yuan L; Chen X; Fan W; Cui M; Song G
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1045-55. PubMed ID: 22392074
[TBL] [Abstract][Full Text] [Related]
5. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts.
Stein GH; Drullinger LF; Soulard A; Dulić V
Mol Cell Biol; 1999 Mar; 19(3):2109-17. PubMed ID: 10022898
[TBL] [Abstract][Full Text] [Related]
6. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis.
Capparelli C; Chiavarina B; Whitaker-Menezes D; Pestell TG; Pestell RG; Hulit J; Andò S; Howell A; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
Cell Cycle; 2012 Oct; 11(19):3599-610. PubMed ID: 22935696
[TBL] [Abstract][Full Text] [Related]
7. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geroconversion.
Leontieva OV; Blagosklonny MV
Cell Cycle; 2013 Sep; 12(18):3063-9. PubMed ID: 23974099
[TBL] [Abstract][Full Text] [Related]
9. Conjugated Physiological Resveratrol Metabolites Induce Senescence in Breast Cancer Cells: Role of p53/p21 and p16/Rb Pathways, and ABC Transporters.
Giménez-Bastida JA; Ávila-Gálvez MÁ; Espín JC; González-Sarrías A
Mol Nutr Food Res; 2019 Nov; 63(22):e1900629. PubMed ID: 31441212
[TBL] [Abstract][Full Text] [Related]
10. Cellular senescence in the response of HR
Klapp V; Buqué A; Bloy N; Sato A; Yamazaki T; Zhou XK; Formenti SC; Galluzzi L; Petroni G
J Transl Med; 2023 Feb; 21(1):110. PubMed ID: 36765430
[TBL] [Abstract][Full Text] [Related]
11. Protective roles of cytoplasmic p21
Koyanagi A; Kotani H; Iida Y; Tanino R; Kartika ID; Kishimoto K; Harada M
Cell Prolif; 2022 Dec; 55(12):e13326. PubMed ID: 36054146
[TBL] [Abstract][Full Text] [Related]
12. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
14. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
15. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
16. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
17. Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity.
Chandra A; Lagnado AB; Farr JN; Doolittle M; Tchkonia T; Kirkland JL; LeBrasseur NK; Robbins PD; Niedernhofer LJ; Ikeno Y; Passos JF; Monroe DG; Pignolo RJ; Khosla S
Aging Cell; 2022 May; 21(5):e13602. PubMed ID: 35363946
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts.
Alcorta DA; Xiong Y; Phelps D; Hannon G; Beach D; Barrett JC
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13742-7. PubMed ID: 8943005
[TBL] [Abstract][Full Text] [Related]
19. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.
Lapillonne H; Konopleva M; Tsao T; Gold D; McQueen T; Sutherland RL; Madden T; Andreeff M
Cancer Res; 2003 Sep; 63(18):5926-39. PubMed ID: 14522919
[TBL] [Abstract][Full Text] [Related]
20. Depletion of γ-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation.
Matsumura K; Nakata S; Taniguchi K; Ii H; Ashihara E; Kageyama S; Kawauchi A; Yoshiki T
BMC Cancer; 2016 Sep; 16(1):748. PubMed ID: 27658708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
